Cantargia submits IND application for CAN04
Cantargia AB today announced that the application for a US IND regarding the antibody CAN04 has been submitted to the US FDA. CAN04, an antibody targeting interleukin 1 receptor accessory protein (IL1RAP), is currently being investigated for treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer (PDAC) in phase IIa clinical development in Europe. The IND application concerns one new phase Ib clinical trial investigating CAN04 in combination with immunotherapy in selected cancer forms overexpressing IL1RAP.Cantargia develops antibody-based pharmaceuticals against the